mail
versión imprimible
 
 

2nd Next Generation Kinase Inhibitors Summit

Evvnt Promotion / evvnt
-
22.02.2023 - 23.02.2023  Boston Park Plaza, 50 Park Plaza, 02116 Boston, USA
Time: 8:00 am to 6:00 pm
 
Temas de la conferencia
With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.
La Sociedad Científica
Hanson Wade
Observaciones
Speakers: Erik Schaefer, Co-Founder, President, Chief Executive Officer and Chief Scientific Officer, AssayQuant Technologies Inc., Gerhard Mueller, Chief Scientific Officer, Anavo Therapeutics, Harish Dave, Chief Medical Officer, AUM Biosciences
 

Información e inscripción:

https://go.evvnt.com/1446853-3?pid=4832
Mr. Min Ratcliffe
 
Categorías
Salud Pública, Servicios de salud
Idioma
Inglés
Cuota del Congreso
Free: USD 0.00
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

European Health Forum GasteinSwiss Tropical and Public Health InstituteCenter of ExcellenceHelix - Forschung & Beratung WienÖsterreichische Akademie der ÄrztenewTreeÖsterreichische Gesellschaft für Public HealthÖsterreichisches Rotes Kreuz